Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares shot up 40% on Friday . The stock traded as high as C$0.04 and last traded at C$0.04. 1,172,033 shares were traded during trading, an increase of 1,485% from the average session volume of 73,952 shares. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Performance
The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The company has a market capitalization of C$5.07 million, a price-to-earnings ratio of -1.50 and a beta of 0.14. The stock’s fifty day simple moving average is C$0.03 and its 200-day simple moving average is C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
See Also
- Five stocks we like better than Quest PharmaTech
- How Can Investors Benefit From After-Hours Trading
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Where to Find Earnings Call Transcripts
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
